01—History
EPS (Diluted) History
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025. Drag across the bars to change the range.
- $2.56
5 older moves run past ±150% (largest +282.0%); point at, tap or drag across the bars to read one.
02—Ledger
03—Questions
What is eps (diluted)?
Diluted earnings per share (EPS) can be defined as net income divided by the total number of shares outstanding including all dilutive securities such as stock options, warrants, and convertible bonds.
What is Halozyme Therapeutics's current eps (diluted)?
Halozyme Therapeutics (HALO) annual eps (diluted) for 2025 was $2.56, a 25.36% decline from 2024. Halozyme Therapeutics eps (diluted) for the quarter ending September 30, 2026 was $2.01.
What was Halozyme Therapeutics's eps (diluted) in 2024?
Halozyme Therapeutics annual eps (diluted) for 2024 was $3.43, a 63.33% increase from 2023.
What was Halozyme Therapeutics's eps (diluted) in 2023?
Halozyme Therapeutics annual eps (diluted) for 2023 was $2.10, a 45.83% increase from 2022.
What is Halozyme Therapeutics's 5-year eps (diluted) CAGR?
Halozyme Therapeutics eps (diluted) grew at a compound annual growth rate (CAGR) of 22.98% from FY2020 to FY2025, going from $0.91 to $2.56 over 5 years.
- Company
- Halozyme Therapeutics
- Ticker
- HALO
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)